Pakistani health authorities have initiated urgent steps to ensure the availability of pharmaceutical supplies following the suspension of trade with India. The Drug Regulatory Authority of Pakistan (DRAP) is actively seeking alternative sources in China, Russia, and Europe for raw materials and critical medicines. In response to the situation, the Pakistan Pharmaceutical Manufacturers Association (PPMA) has called on the government to consider exempting the pharmaceutical sector from the trade halt to prevent potential shortages of vital medications. This move comes in the wake of the recent Pahalgam terror attack, which led to the deterioration of diplomatic relations between India and Pakistan. By diversifying its sources for pharmaceutical ingredients and medicines, Pakistan aims to mitigate the impact of the trade restrictions on its healthcare system. The health sector plays a crucial role in ensuring the well-being of the population, and any disruptions in the drug supply chain could have serious consequences. As Pakistan navigates through this challenging period, collaboration with alternative suppliers and regulatory flexibility will be key to maintaining uninterrupted access to essential healthcare products.